Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

89bio inc. - ETNB

ETNB

Close Chg Chg %
8.38 0.44 5.25%

Open Market

8.82

+0.44 (5.25%)

Volume: 224.63K

Last Updated:

Nov 22, 2024, 2:51 PM EDT

Trade Now

Company Overview: 89bio inc. - ETNB

ETNB Key Data

Open

$8.42

 Day Range

8.30 - 8.91

52 Week Range

7.00 - 16.63

 Market Cap

$985.34M

Shares Outstanding

117.58M

 Public Float

112.43M

Beta

0.98

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.91

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

939.34K

  

ETNB Performance

1 Week
 
 5.67%
 
1 Month
 
 6.48%
 
3 Months
 
 -5.36%
 
1 Year
 
 5.81%
 
5 Years
 
 -72.00%
 

ETNB Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About 89bio inc. - ETNB

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

ETNB At a Glance

89bio, Inc.
142 Sansome Street
San Francisco, California 94104
Phone 1-415-432-9270 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -142,189,000.00
Sector Health Technology Employees 70
Fiscal Year-end 12 / 2024
View SEC Filings

ETNB Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.943
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.612
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.111

ETNB Efficiency

Revenue/Employee N/A
Income Per Employee -2,031,271.429
Receivables Turnover N/A
Total Asset Turnover N/A

ETNB Liquidity

Current Ratio 20.044
Quick Ratio 20.044
Cash Ratio 19.549

ETNB Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -35.857
Return on Equity -41.326
Return on Total Capital -25.237
Return on Invested Capital -38.711

ETNB Capital Structure

Total Debt to Total Equity 5.055
Total Debt to Total Capital 4.811
Total Debt to Total Assets 4.546
Long-Term Debt to Equity 4.962
Long-Term Debt to Total Capital 4.723
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for 89bio Inc. - ETNB

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
60.00K 79.00K 240.00K 273.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
60.00K 79.00K 240.00K 273.00K
Depreciation
60.00K 79.00K 240.00K 273.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+252.94% +31.67% +203.80% +13.75%
Gross Income
(60.00K) (79.00K) (240.00K) (273.00K)
Gross Income Growth
-252.94% -31.67% -203.80% -13.75%
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
49.30M 89.66M 102.01M 150.93M
Research & Development
36.20M 70.33M 80.80M 122.23M
Other SG&A
13.10M 19.33M 21.21M 28.70M
SGA Growth
+85.16% +81.89% +13.77% +47.96%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.21M
-
EBIT after Unusual Expense
(49.35M) (89.74M) (102.25M) (152.41M)
Non Operating Income/Expense
(203.00K) (526.00K) 2.16M 17.68M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 1.92M 3.59M
-
Interest Expense Growth
- - - +86.58%
-
Gross Interest Expense
- - 1.92M 3.59M
-
Interest Capitalized
- - - -
-
Pretax Income
(49.56M) (90.27M) (102.01M) (138.32M)
Pretax Income Growth
+13.36% -82.15% -13.00% -35.60%
Pretax Margin
- - - -
-
Income Tax
(59.00K) (147.00K) 19.00K 3.87M
Income Tax - Current - Domestic
- 10.00K 2.00K 3.00K
Income Tax - Current - Foreign
- 1.00K 16.00K 3.74M
Income Tax - Deferred - Domestic
- - (69.00K) (150.00K)
-
Income Tax - Deferred - Foreign
- - - 127.00K
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(49.50M) (90.12M) (102.03M) (142.19M)
Minority Interest Expense
- - - -
-
Net Income
(49.50M) (90.12M) (102.03M) (142.19M)
Net Income Growth
+13.79% -82.07% -13.21% -39.37%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(49.50M) (90.12M) (102.03M) (142.19M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(49.50M) (90.12M) (102.03M) (142.19M)
EPS (Basic)
-3.0768 -4.484 -2.9312 -1.9978
EPS (Basic) Growth
+87.44% -45.74% +34.63% +31.84%
Basic Shares Outstanding
16.09M 20.10M 34.81M 71.17M
EPS (Diluted)
-3.0768 -4.484 -2.9312 -1.9978
EPS (Diluted) Growth
+87.44% -45.74% +34.63% +31.84%
Diluted Shares Outstanding
16.09M 20.10M 34.81M 71.17M
EBITDA
(49.30M) (89.66M) (102.01M) (150.93M)
EBITDA Growth
-85.16% -81.89% -13.77% -47.96%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 31.00
Number of Ratings 8 Current Quarters Estimate -0.755
FY Report Date 12 / 2024 Current Year's Estimate -3.177
Last Quarter’s Earnings -1.39 Median PE on CY Estimate N/A
Year Ago Earnings -2.00 Next Fiscal Year Estimate -2.932
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 3 8 8
Mean Estimate -0.75 -0.67 -3.18 -2.93
High Estimates -0.56 -0.60 -2.96 -2.43
Low Estimate -1.03 -0.70 -3.50 -3.77
Coefficient of Variance -25.98 -8.83 -6.21 -16.24

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 5 6
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for 89bio Inc. - ETNB

Date Name Shares Transaction Value
Aug 20, 2024 Harry H. Mansbach Chief Medical Officer 157,391 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.04 per share 1,265,423.64
Aug 20, 2024 Rohan Palekar Chief Executive Officer; Director 456,236 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.04 per share 3,668,137.44
Aug 20, 2024 Ryan Stephen Martins Chief Financial Officer 105,832 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.04 per share 850,889.28
Aug 20, 2024 Quoc Le-Nguyen See Remarks 221,103 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.04 per share 1,777,668.12
May 6, 2024 Martin Babler Director 67,700 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 16, 2024 RA Capital Management LP Director 13,840,034 Exercise of in-the-money or at-the-money derivative security Non-derivative transaction at $5.32 per share 73,628,980.88
Apr 16, 2024 RA Capital Management LP Director 27,400 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 16, 2024 RA Capital Management LP Director 45,150 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 16, 2024 RA Capital Management LP Director N/A Exercise of in-the-money or at-the-money derivative security 0.00
Apr 4, 2024 Rohan Palekar Chief Executive Officer; Director 459,171 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.91 per share 5,009,555.61
Apr 4, 2024 Rohan Palekar Chief Executive Officer; Director 120,231 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

89bio Inc. in the News